XTX Topco Ltd purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 83,547 shares of the company's stock, valued at approximately $565,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of RXRX. Vanguard Group Inc. increased its holdings in Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after buying an additional 9,737,196 shares during the period. Norges Bank purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $23,429,000. Geode Capital Management LLC raised its position in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after acquiring an additional 656,003 shares in the last quarter. Institute for Wealth Management LLC. purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $3,928,000. Finally, Platinum Investment Management Ltd. boosted its position in Recursion Pharmaceuticals by 293.9% during the fourth quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company's stock valued at $4,955,000 after purchasing an additional 546,929 shares in the last quarter. Institutional investors own 89.06% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on RXRX shares. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Morgan Stanley dropped their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Finally, KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $8.20.
Read Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Performance
Shares of NASDAQ RXRX opened at $5.50 on Friday. The company has a 50 day simple moving average of $6.62 and a two-hundred day simple moving average of $6.80. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -3.59 and a beta of 1.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.42) EPS. As a group, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
About Recursion Pharmaceuticals
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
